. Author manuscript; available in PMC: 2022 Feb 28.

Published in final edited form as: N Engl J Med. 2021 Jul 29;385(5):436–444. doi: 10.1056/NEJMoa1913569

Table 4.

Maternal Secondary Outcomes.^*

Outcome	Hyperimmune Globulin (N = 205)	Placebo (N = 193)	Relative Risk (95% CI)
	no. (%)
Gestational diabetes	5 (2.4)	7 (3.6)	0.67 (0.22–2.08)
Clinical chorioamnionitis	7 (3.4)	7 (3.6)	0.94 (0.34–2.63)
Oligohydramnios^†	10 (4.9)	3 (1.6)	3.14 (0.93–15.10)
Polyhydramnios^†	6 (2.9)	3 (1.6)	1.88 (0.45–14.06)
Gestational hypertension or preeclampsia	24 (11.7)	14 (7.3)	1.61 (0.86–3.03)
Placental abruption^†	3 (1.5)	1 (0.5)	2.82 (0.29–72.42)
Cesarean delivery	51 (24.9)	49 (25.4)	0.98 (0.70–1.38)

All available maternal data are shown; values are missing for one participant in the hyperimmune globulin group. The 95% confidence intervals are not adjusted for multiplicity, so these values should not be used to infer definitive treatment effects.

^†

Exact confidence limits were calculated for rare outcomes with the use of StatXact software (Cytel).